Text Version
Entrez PubMed
Overview
Help | FAQ
Tutorial
New/Noteworthy
E-Utilities
PubMed Services
Journals Database
MeSH Database
Single Citation Matcher
Batch Citation Matcher
Clinical Queries
LinkOut
Cubby
Related Resources
Order Documents
NLM
Gateway
TOXNET
Consumer
Health
Clinical Alerts
ClinicalTrials.gov
PubMed
Central
Privacy Policy
|
 |
-
Reports of withdrawal syndrome
with the use of SSRIs: a case/non-case study in the French
Pharmacovigilance database.
Trenque T, Piednoir D,
Frances C, Millart H, Germain ML.
Regional Pharmacovigilance
Centre Champagne-Ardenne, Centre Hospitalier Universitaire, 45 Rue
Cognacq-Jay, 51092 Reims, France. ttrenque@chu-reims.fr
The SSRIs
can be associated with withdrawal reactions and the objective of this
study is to test the existence of an association between reports of
withdrawal syndromes with the selective serotonin re-uptake inhibitors
in the French spontaneous reports database. All reactions are coded
according to the WHO ART dictionary. Cases are reports of reactions of
interest (withdrawal syndrome). Non-cases are all reports of reactions
other than those being studied. We calculated the odds ratio (OR) as the
ratio of the odds of the association of reports of withdrawal syndrome
with SSRIs in cases and non-cases. SSRIs are clearly associated with a
higher risk of withdrawal syndrome (OR: 5.05, 95% CI: 3.81-6.68) and in
particular with venlafaxine and paroxetine (OR: 12.16, 95% CI:
6.17-23.35 and OR: 8.47, 95% CI: 5.63-12.65, respectively). The risk of
withdrawal reactions appears to be greater with short half-life drugs
such as paroxetine and venlafaxine. The precise mechanisms have not been
identified.
PMID: 12138595 [PubMed - indexed for MEDLINE]
|